Results 21 to 30 of about 1,141 (182)

Rezafungin as Primary Prophylaxis of Pneumocystis jirovecii Pneumonia in a Critically Ill Person Presenting with AIDS with Trimethoprim/Sulfamethoxazole Allergy: A Case Report [PDF]

Journal of Fungi
Primary prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in people with HIV (PWH) and CD4+ counts
Martina Bottanelli, Alice Mulè, Chiara Molteni, Martina Gerbi, Mauro Pietro Zago, Sara Volpi, Sofia Pettenuzzo, Alessandro Pandolfo, Valentina Morena, Nicole Gemignani, Michele Fogliata, Federico Conti, Alessandra Consonni, Lucia Bradanini, Silvia Pontiggia, Stefania Piconi   +15 more
doaj   +2 more sources

Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States. [PDF]

Mycoses
ABSTRACTBackgroundRezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.MethodsA retrospective analysis of patients treated with ...
Reinhold I, Mori G, Lanzafame M, Limongelli A, Vena A, Götz J, Bauernfeind S, Hanses F, Tometten L, Mayer M, Rieke A, Soriano-Martin A, Valerio M, Vazquez JA, Yue P, Rahimli L, Azimli N, Sal E, Salmanton-García J, Vasenda N, Sprute R, Stemler J, Wingen-Heimann S, Cornely OA, Seidel D.   +24 more
europepmc   +3 more sources

FDA-approved drugs featuring macrocycles or medium-sized rings [PDF]

Archiv der Pharmazie, Volume 358, Issue 1, January 2025.
Macrocycles or medium-sized rings offer diverse functionality and stereochemical complexity in a well-organized ring structure, allowing them to fulfill various biochemical functions, resulting in high affinity and selectivity for protein targets, while ...
Baecker, Daniel, Du, Youlong, Han, Jianlin, Kiss, Loránd, Mei, Haibo, Semghouli, Anas, Soloshonok, Vadim A., Wang, Qian   +7 more
core   +2 more sources

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin

IDCases
Antifungal resistance in Candida glabrata can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves.
Divya Chandramohan, Samantha Aguilar, Gerard Gawrys, Nathan P. Wiederhold, Kristi Traugott, Thomas F. Patterson   +5 more
doaj   +3 more sources

The In Vitro Activity of Rezafungin Against Uncommon Species of Candida

Mycoses
ABSTRACTBackgroundInvasive candidiasis (IC) is increasing due to the rising numbers of immunocompromised patients. Increasing azole resistance rates and daily dosing required for most echinocandins have complicated its treatment. The approval of rezafungin has provided an option for weekly echinocandin treatment.
Marisa L. Winkler, Paul Rhomberg, Abigail L. Klauer, Samuel Edeker, Mariana Castanheira   +4 more
openaire   +3 more sources

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Microorganisms
Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months.
Giulio Viceconte, Antonio Riccardo Buonomo, Nunzia Esposito, Letizia Cattaneo, Teresa Somma, Maria Michela Scirocco, Ciro Gabriele Mainolfi, Ivan Gentile   +7 more
doaj   +4 more sources

Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom. [PDF]

Mycoses
ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Muszbek N, Angdembe A, Garcia-Vidal C, Bielicka I, Abrams KR, Tolley K, Ruhnke M, Lebmeier M, Hawkins N, Manamley N, Dickerson S.   +10 more
europepmc   +2 more sources

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice. [PDF]

Mycoses
ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Boán J, Aparicio-Minguijón E, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Rodríguez-Goncer I, López-Medrano F, San-Juan R, Silva JT, Pérez-Ayala A, Caro-Teller JM, Aguado JM.   +10 more
europepmc   +2 more sources

Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China). [PDF]

Mycoses
ABSTRACT Background The global double‐blind, randomised, Phase 3 ReSTORE trial (NCT03667690) demonstrated noninferiority of rezafungin versus caspofungin for all‐cause mortality at Day 30 and global cure at Day 14 in patients with candidemia and/or invasive candidiasis.
Huang H, Feng S, Yu Y, Zhang Y, Yuan Y, Cox L, Zhang Y.   +6 more
europepmc   +2 more sources

The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice. [PDF]

Mycoses
ABSTRACT Invasive candidiasis is a life‐threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifungal treatment are essential to improving patient outcomes and limiting unnecessary use of healthcare resources.
Cornely OA, Bassetti M, Garcia-Vidal C, Hoenigl M, Maertens J, Martin-Loeches I, Mira JP, White PL.   +7 more
europepmc   +2 more sources